Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Georgia's congressional delegation is advocating for FDA reconsideration of the drug elamipretide for Hope Filchak.

The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has ... I urge Gilead to do the right thing. Drop the price, expand production, and ensure the world has a shot ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

Kisqali will be expensive The cost, out-of-pocket, three-year dose of Kisqali will be close to $300,000-$400,000. However, with the expanded approval, scientists say it is more likely that insurance ...

WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.